Compare
VivoSim Labs, Inc. vs aTYR PHARMA INC vs Cardiff Oncology, Inc. vs ImageneBio, Inc.
| Latest fiscal year | VivoSim Labs, Inc. VIVS | aTYR PHARMA INC ATYR | Cardiff Oncology, Inc. CRDF | ImageneBio, Inc. IMA |
|---|---|---|---|---|
| Year ended | 2026-03-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $131.0K | $190.0K | $593.0K | $800.0K |
| Revenue growth (YoY) | -9.0% | -19.1% | -13.2% | -77.1% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$13.84M | -$74.12M | -$45.85M | -$45.35M |
| EPS (Diluted) | -$5.35 | -$0.80 | -$0.69 | -$9.64 |
| Operating cash flow | -$10.83M | -$61.99M | -$37.92M | -$47.84M |
| Free cash flow | -$10.83M | -$62.06M | -$37.97M | n/a |
| Cash & equivalents | $5.02M | $10.74M | $17.47M | $94.53M |
| Total assets | $7.39M | $93.00M | $61.88M | $152.98M |
| Total liabilities | $8.48M | n/a | $16.50M | $19.84M |
| Shareholders' equity | -$1.10M | $67.48M | $45.39M | $133.14M |
| Return on year-end equity | n/a | -109.8% | -101.0% | -34.1% |
| Shares outstanding | 2.89M | 98.03M | 68.31M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | VivoSim Labs, Inc. | aTYR PHARMA INC | Cardiff Oncology, Inc. | ImageneBio, Inc. |
|---|---|---|---|---|
| Latest | $131.0K Ended 2026-03-31 | $190.0K Ended 2025-12-31 | $593.0K Ended 2025-12-31 | $800.0K Ended 2025-12-31 |
| 1 year earlier | $144.0K Ended 2025-03-31 | $235.0K Ended 2024-12-31 | $683.0K Ended 2024-12-31 | $3.50M Ended 2024-12-31 |
| 2 years earlier | $109.0K Ended 2024-03-31 | $353.0K Ended 2023-12-31 | $488.0K Ended 2023-12-31 | $9.16M Ended 2023-12-31 |
| 3 years earlier | $370.0K Ended 2023-03-31 | $10.39M Ended 2022-12-31 | $386.0K Ended 2022-12-31 | $15.62M Ended 2022-12-31 |
| 4 years earlier | $1.50M Ended 2022-03-31 | $0 Ended 2021-12-31 | $359.0K Ended 2021-12-31 | $30.98M Ended 2021-12-31 |